Nepanizil (Donepezil Hydrochloride)

Donepezil works by reversibly inhibiting acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the brain. This inhibition raises acetylcholine levels, enhancing cholinergic neurotransmission that supports learning, memory, and overall cognitive performance.

The dosage of Donepezil is individualized by the prescribing clinician based on patient characteristics. A common starting regimen is 5 mg taken once daily, which may be increased to 10 mg once daily if tolerated, but the exact dose must follow the prescriber’s order.

Safety of Donepezil in pregnancy and lactation has not been established; it is classified as a pregnancy category unknown. Use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Nepanizil product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Donepezil belongs to the acetylcholinesterase inhibitor class, similar to rivastigmine and galantamine. Compared with these agents, Donepezil is typically administered once daily, has a longer half‑life, and is often preferred for its convenient dosing and tolerability, although individual response may vary.

Nepanizil tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Nepanizil is taken orally as a whole tablet swallowed with water, with or without food. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments, and should not crush or chew the tablet unless specifically directed by a healthcare professional.

Serious adverse events linked to Donepezil include significant bradycardia or other cardiac conduction problems, severe gastrointestinal bleeding or ulceration, hepatic injury, rare seizures, and severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if these symptoms occur.

Contraindications include patients with known hypersensitivity to Donepezil or any excipients, those with severe cardiac conduction disorders, active peptic ulcer disease, or individuals taking medications that may cause dangerous additive cholinergic effects. Clinicians should evaluate each patient’s medical history before initiating therapy.